Treatment for advanced solid tumors with c-MET gene changes

A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration

This study is testing a new drug called ABN401 to see if it can help people with advanced solid tumors that have c-MET gene changes when other treatments haven't worked.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 19 Years and up
• Sex: All
• Sponsor: Yonsei University (other)
• Drugs / interventions: Chemotherapy, capmatinib
• Locations: 1 site (Seoul, Seoul)
• Trial ID: NCT05882292 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the efficacy of ABN401, a c-MET inhibitor, in patients with advanced solid tumors that exhibit c-MET gene aberrations. Participants will receive ABN401 orally once daily after meals for a 21-day cycle, with treatment continuing until disease progression or unacceptable toxicity occurs. The trial aims to determine the drug's effectiveness based on disease control rates among enrolled patients, with a focus on those who have not responded to standard therapies.

Who should consider this trial

Good fit: Ideal candidates include adults aged 19 and older with histologically confirmed advanced solid cancers harboring specific c-MET alterations.

Not a fit: Patients with non-small cell lung cancer exhibiting exon 14 skipping mutations may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors that have limited treatment alternatives.

How similar studies have performed: Other studies targeting c-MET inhibition have shown promise, indicating potential for success with this approach.

Eligibility criteria

Inclusion Criteria:

1. Informed consent for KOSMOS-II master observation study
2. Male or female ≥19 years of age
3. Histologically confirmed advanced solid cancers who harboring c-MET alterations (patients who performed NGS tests and c-MET alterations confirmed in molecular tumor board \[MTB\]) - exon 14 skipping mutation except for non-small cell lung cancer (NSCLC)

   * c-MET amplification GCN (gene copy no.) ≥6 by NGS
   * Fluorescence/Silver In situ hybridization (FISH/SISH) result of the MET/CEP7 ratio ≥2
   * Other MET alterations that are regarded to be actionable by the KOSMOS MTB
4. Disease progression during or after standard therapy and without further treatment options, or no standard therapy, or ineligible for standard therapy
5. At least one measurable or evaluable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
6. Eastern Cooperative Oncology Group Performance Status 0-2
7. Capable to eat food
8. Adequate organ functions

   * Absolute neutrophil count (ANC) ≥1500/mm3 (ie, 1.5×109/L by International - Unit \[IU\]); excluding measurements obtained within 7 days after administration of granulocyte colony stimulating factor (G-CSF)
   * Platelet count ≥75000/mm3 (IU: ≥75×109/L); excluding measurements obtained within 7 days after transfusion of platelets.
   * Hemoglobin value of ≥8.0 g/dL
   * AST/ALT ≤3×upper limit of normal (ULN); if liver function abnormalities are due to underlying liver metastasis, AST / ALT ≤5×ULN
   * Total serum bilirubin of ≤1.5×ULN
   * Creatinine clearance (CrCl) of ≥50 mL/min (MDRD)
9. Have a life expectancy of at least 90 days
10. If not menopausal or surgically sterile, willing to practice at least one of the following highly effective methods of birth control for at least a (partner's) menstrual cycle before and for 3 months after study drug administration:

    * Barrier type devices (examples are condom, diaphragm, and contraceptive sponge) used only in combination with a spermicide
    * Sexual intercourse with vasectomized male/sterilized female partner
    * Hormonal female contraceptive (oral, parenteral, intravaginal, implantable, or transdermal) for at least 3 consecutive months prior to investigational product administration (when not clinically contraindicated as in breast, ovarian and endometrial cancers)
    * Use of an intrauterine contraceptive device

      * Note: Abstinence, the rhythm method, and/or contraception by the partner are not acceptable methods of birth control
11. Willing to provide available tissue specimens and consent to blood collection for evaluation of biomarkers

    * Archival tissue specimens: formalin-fixed, paraffin-embedded tissues
    * Optional fresh tissue collection prior to ABN401 administration

Exclusion Criteria:

1. Previous treatment with c-MET inhibitor
2. NSCLC with c-MET exon 14 skipping mutation
3. Previous hypersensitivity reaction to any component of study drugs
4. Presence or history of arrhythmia
5. Past history of

   ① Major surgery within 4 weeks before study (must have complete recovery from surgical complications)

   ② Radiotherapy within 4 weeks before study or limited radiotherapy within 2 weeks

   ③ Chemotherapy or biologic agents within 3 weeks before study (targeted therapy within 2 weeks and mitomycin within 5 weeks)
6. History of the following medical conditions

   * Active central nervous system (CNS) metastasis (clinically unstable after stopping steroid for more than 2 months)
   * Leptomeningeal metastasis
   * Acute systemic infection
   * Acute myocardial infarction, stable/unstable angina, symptomatic heart failure ((New York Heart Association \[NYHA\] class III or IV within the previous 6 months; if \>6 months cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms)
   * Clinically critical chronic vomiting or diarrhea
   * Uncontrolled hypertension (systolic blood pressure \>150mmHg diastolic blood pressure\>100mmHg)
   * Proteinuria (urine dipstick or 24-hour urine collection \> 1.0g): must have 24-hour urine collection if baseline urine dipstick ≥2+
   * Active HBV/ HCV except for

     * HBsAg (+) with undetectable HBV DNA
     * If HBsAg (+) and HBV DNA (+), chronic state of infection and clinically stable after anti-viral therapy for more than 3 months
     * If IgG anti-HBc (+) and past history of HBV infection, undetectable HBV DNA
     * HCV Ab (+) with undetectable HCV RNA
   * Severe psychiatric disorders
   * Concurrent anticoagulants at therapeutic dose
   * Past history of gastrointestinal perforation or fistula within 3 months before study, grade 3 or 4 of gastrointestinal bleeding/varix
7. Toxicity with prior therapy (\> grade 1) (except for alopecia, pigmentation, poor oral intake), and neuropathy (\> grade 1)
8. Pregnant or breastfeeding
9. Patients with a corrected QT interval (using Fridericia's correction formula) (QTcF) of \> 470 msec

Where this trial is running

Seoul, Seoul

• minkyu Jung — Seoul, Seoul, South Korea (RECRUITING)

Study contacts

• Principal investigator: minkyu Jung — Yonsei Cencer center
• Study coordinator: minkyu Jung

Conditions: Neoplasms, ABN401, c-MET gene aberration, solid tumors